Pathophysiology of Thoracic Aortic Aneurysm (TAA): Is It Not One Uniform Aorta? Role of Embryologic Origin

Progress in Cardiovascular Diseases

Volumn 56, Issue 1, 2013, Pages 68-73

  Ruddy, Jean Marie ^a,b   Jones, Jeffery A ^a,b   Ikonomidis, John S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Extracellular matrix remodeling; Matrix metalloproteinases; Thoracic Aortic Aneurysm; Transforming growth factor beta

Indexed keywords

ANGIOTENSIN II; COLLAGEN; COLLAGEN TYPE 3; ELASTIN; FIBRILLIN 1; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN HEAVY CHAIN BETA; SMOOTH MUSCLE ACTIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ABDOMINAL AORTA ANEURYSM; ACTA2 GENE; ARTERY COMPLIANCE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BIOCHEMISTRY; COL3A1 GENE; DISEASE COURSE; DISEASE MODEL; EHLERS DANLOS SYNDROME; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FBN1 GENE; GENE; GENE MUTATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; LOEYS DIETZ SYNDROME; MARFAN SYNDROME; MYH11 GENE; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TGFBR1 GENE; TGFBR2 GENE; THORACIC AORTA ANEURYSM; VASCULAR SMOOTH MUSCLE;

AAA; ABDOMINAL AORTIC ANEURYSM; ANGII; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR 1; AT1; ECM; ERK; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX REMODELING; EXTRACELLULAR SIGNAL-REGULATED KINASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASES; MMP; T-PA; TAA; TGF-Β; TGF-ΒR1 & 2; THORACIC AORTIC ANEURYSM; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 & 2; TRANSFORMING GROWTH FACTOR-BETA; VASCULAR SMOOTH MUSCLE CELL; VSMC;

ANIMALS; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; MATRIX METALLOPROTEINASES; PEDIGREE; PHENOTYPE; PROGNOSIS; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84883051112     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2013.04.002     Document Type: Article

References (57)

1. National Center for Injury Prevention and Control. WISQARS Leading Causes of Death Reports, 1999-2006. Available at, http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html.
2. Coady M.A., Rizzo J.A., Elefteriades J.A. Developing surgical intervention criteria for thoracic aortic aneurysms. Card Clin 1999, 17:827-839.
3. Ruddy J.M., Jones J.A., Spinale F.G., Ikonomidis J.S. Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg 2008, 136:1123-1130.
4. Castellano J.M., Kovacic J.C., Sanz J., Fuster V. Are we ignoring the dilated thoracic aorta?. Ann N Y Acad Sci 2012, 1254:164-174.
5. Wolinsky H. Comparison of medial growth of human thoracic and abdominal aortas. Circ Res 1970, 27:531-538.
6. Halloran B.G., Davis V.A., McManus B.M., Lynch T.G., Baxter B.T. Localization of aortic disease is associated with intrinsic differences in aortic structure. J Surg Res 1995, 59:17-22.
7. Steed M.M., Tyagi S.C. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antiox Redox Sign 2011, 15:1927-1943.
8. Zhou J., Austin R.C. Contributions of hyperhomocysteinemia to atherosclerosis: causal relationship and potential mechanisms. Biofactors 2009, 35:120-129.
9. Steed M.M., Tyagi N., Sen U., Schuschke D.A., Joshua I.G., Tyagi S.C. Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type, eNOS-/-, and iNOS-/- mice. Am J Physiol Lung Cell Mol Physiol 2010, 299:L301-L311.
10. Dalton M.L., Gadson P.F., Wrenn R.W., Rosenquist T.H. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB 1997, 11:703-711.
11. Jones J.A., Barbour J.R., Lowry A.S., et al. Spatiotemporal expression and localization of matrix metalloproteinas-9 in a murine model of thoracic aortic aneurysm. J Vasc Surg 2006, 44:1314-1321.
12. Bruemmer D., Daugherty A., Lu H., Rateri D.L. Relevance of angiotensin II-induced aortic pathologies in mice to human aortic aneurysms. Ann N Y Acad Sci 2011, 1245:7-10.
13. Rateri D.L., Howatt D.A., Moorleghen J.J., Charnigo R., Cassis L.A., Daugherty A. Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol 2011, 179:1542-1548.
14. Beck L., D'Amore P.A. Vascular development: cellular and molecular regulation. FASEB 1997, 11:365-373.
15. Gadson P.F., Dalton M.L., Patterson E., et al. Differential response of mesoderm- and neural crest-derived smooth muscle to TGF-beta1: regulation of c-myb and alpha1 (I) procollagen genes. Ex Cell Res 1997, 230:169-180.
16. Thieszen S.L., Dalton M., Gadson P.F., Patterson E., Rosenquist T.H. Embryonic lineage of vascular smooth muscle cells determines responses to collagen matrices and integrin receptor expression. Exp Cell Res 1996, 227:135-145.
17. El-Hamamsy I., Yacoub M.H. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nature Rev Cardiology 2009, 6:771-786.
18. Wrana J.L., Attisano L., Wieser R., Ventura F., Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347.
19. Leivonen S.K., Chantry A., Hakkinen L., Han J., Kahari V.M. Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J Biol Chem 2002, 277:46338-46346.
20. Kucich U., Rosenbloom J.C., Abrams W.R., Rosenbloom J. Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta, and p38. Am J Resp Cell Mol Biol 2002, 26:183-188.
21. Kwak H.J., Park M.J., Cho H., et al. Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. MCR 2006, 4:209-220.
22. Kim E.S., Kim M.S., Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int Journal Oncol 2004, 25:1375-1382.
23. Holm T.M., Habashi J.P., Doyle J.J., et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011, 332:358-361.
24. Feng X.H., Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Ann Rev Cell Devel Biol 2005, 21:659-693.
25. Suszko M.I., Woodruff T.K. Cell-specificity of transforming growth factor-beta response is dictated by receptor bioavailability. J Mol Endocrinol 2006, 36:591-600.
26. Barbour J.R., Spinale F.G., Ikonomidis J.S. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res 2007, 139:292-307.
27. Sinha I., Bethi S., Cronin P., et al. A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2. J Vasc Surg 2006, 43:342-348.
28. Laiho M., Saksela O., Keski-Oja J. Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 1986, 164:399-407.
29. Sherratt M.J., Baldock C., Haston J.L., et al. Fibrillin microfibrils are stiff reinforcing fibres in compliant tissues. J Mol Biol 2003, 332:183-193.
30. Chaudhry S.S., Cain S.A., Morgan A., Dallas S.L., Shuttleworth C.A., Kielty C.M. Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 2007, 176:355-367.
31. Bax D.V., Mahalingam Y., Cain S., et al. Cell adhesion to fibrillin-1: identification of an Arg-Gly-Asp-dependent synergy region and a heparin-binding site that regulates focal adhesion formation. J Cell Sci 2007, 120:1383-1392.
32. van der Rest M., Garrone R. Collagen family of proteins. FASEB 1991, 5:2814-2823.
33. Goel S.A., Guo L.W., Shi X.D., et al. Preferential secretion of collagen type 3 versus type 1 from adventitial fibroblasts stimulated by TGF-beta/Smad3-treated medial smooth muscle cells. Cell Sign 2012, 25:955-960.
34. Dietz H.C., Loeys B., Carta L., Ramirez F. Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Gen 2005, 139C:4-9.
35. De Paepe A., Devereux R.B., Dietz H.C., Hennekam R.C., Pyeritz R.E. Revised diagnostic criteria for the Marfan syndrome. Am J Med Gen 1996, 62:417-426.
36. van Karnebeek C.D., Naeff M.S., Mulder B.J., Hennekam R.C., Offringa M. Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 2001, 84:129-137.
37. Bunton T.E., Biery N.J., Myers L., Gayraud B., Ramirez F., Dietz H.C. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001, 88:37-43.
38. Neptune E.R., Frischmeyer P.A., Arking D.E., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nature Gen 2003, 33:407-411.
39. Habashi J.P., Judge D.P., Holm T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121.
40. Habashi J.P., Doyle J.J., Holm T.M., et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011, 332:361-365.
41. Loeys B.L., Chen J., Neptune E.R., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature Gen 2005, 37:275-281.
42. Pepin M., Schwarze U., Superti-Furga A., Byers P.H. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. New Eng J Med 2000, 342:673-680.
43. Germain D.P. Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis 2007, 2:32.
44. Loeys B.L., Schwarze U., Holm T., et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. New Eng J Med 2006, 355:788-798.
45. Albornoz G., Coady M.A., Roberts M., et al. Familial thoracic aortic aneurysms and dissections - incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg 2006, 82:1400-1405.
46. Guo D.C., Pannu H., Tran-Fadulu V., et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nature Gen 2007, 39:1488-1493.
47. Zhu L., Vranckx R., Khau Van Kien P., et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nature Gen 2006, 38:343-349.
48. He R, Guo DC, Sun W, et al. Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms. J Thorac Cardiovasc Surg 2008;136:922-9, 9 e1.
49. Pannu H., Tran-Fadulu V., Papke C.L., et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Human Mol Gen 2007, 16:2453-2462.
50. Pannu H., Fadulu V.T., Chang J., et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005, 112:513-520.
51. Jones J.A., Spinale F.G., Ikonomidis J.S. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res 2009, 46:119-137.
52. Cohn R.D., van Erp C., Habashi J.P., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nature Med 2007, 13:204-210.
53. Zhou Y., Poczatek M.H., Berecek K.H., Murphy-Ullrich J.E. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Comm 2006, 339:633-641.
54. Subramanian V., Golledge J., Heywood E.B., Bruemmer D., Daugherty A. Regulation of peroxisome proliferator-activated receptor-gamma by angiotensin II via transforming growth factor-beta1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells. Atheroscler Thromb Vasc Biol 2012, 32:397-405.
55. O'Rourke J.R., Olson E.N. Modulating the MicroRNArchitecture of an aging aorta. Circ Res 2011, 109:1098-1099.
56. Merk D.R., Chin J.T., Dake B.A., et al. miR-29b participates in early aneurysm development in Marfan syndrome. Circ Res 2012, 110:312-324.
57. Jones J.A., Stroud R.E., O'Quinn E.C., et al. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Gen 2011, 4:605-613.